A major supplier of drug testing kits has announced an updated screening panel which no longer tests for cannabis and prioritizes testing for fentanyl. Traditional 5-panel drug tests, rooted in a four-decade-old paradigm, have failed to evolve in today’s drug market and are unable to detect the rising drug, fentanyl,” Psychemedics said in a press release. A report by Global Market Insights valued the drug testing market size at $6.2 billion in 2022 and estimated the market would jump 16.3% over the next decade to reach $27.1 billion by 2022. Psychemedics drug tests, which use hair as opposed to urine, are also reportedly much more effective than the urine tests at detecting other drugs besides cannabis as well. Psychemedics, according to their website, supplies pre-employment and employee drug screening services to thousands of companies including several companies listed within the Fortune 500.
A major supplier of drug testing kits has announced an updated screening panel which no longer tests for cannabis and prioritizes testing for fentanyl.
Psychemedics, a Massachusetts-based producer of drug testing kits announced Friday that they would be launching a new five-panel drug screen which will “[shift] the spotlight from marijuana to the paramount threat of fentanyl” amid a nationally changing legislative landscape with regard to cannabis laws and continually skyrocketing...
Read the full article @ High Times